These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 35450967)
21. Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging. Wang Q; Schindler SE; Chen G; Mckay NS; McCullough A; Flores S; Liu J; Sun Z; Wang S; Wang W; Hassenstab J; Cruchaga C; Perrin RJ; Fagan AM; Morris JC; Wang Y; Benzinger TLS Neurology; 2024 Feb; 102(4):e208013. PubMed ID: 38315956 [TBL] [Abstract][Full Text] [Related]
22. Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. Ramanan VK; Graff-Radford J; Syrjanen J; Shir D; Algeciras-Schimnich A; Lucas J; Martens YA; Carrasquillo MM; Day GS; Ertekin-Taner N; Lachner C; Willis FB; Knopman DS; Jack CR; Petersen RC; Vemuri P; Graff-Radford N; Mielke MM Neurology; 2023 Oct; 101(14):e1402-e1411. PubMed ID: 37580163 [TBL] [Abstract][Full Text] [Related]
23. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Aschenbrenner AJ; Li Y; Henson RL; Volluz K; Hassenstab J; Verghese P; West T; Meyer MR; Kirmess KM; Fagan AM; Xiong C; Holtzman D; Morris JC; Bateman RJ; Schindler SE Ann Clin Transl Neurol; 2022 Nov; 9(11):1739-1751. PubMed ID: 36183195 [TBL] [Abstract][Full Text] [Related]
24. The dynamics of plasma biomarkers across the Alzheimer's continuum. Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875 [TBL] [Abstract][Full Text] [Related]
25. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly. Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353 [TBL] [Abstract][Full Text] [Related]
26. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632 [TBL] [Abstract][Full Text] [Related]
27. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. Palmqvist S; Janelidze S; Stomrud E; Zetterberg H; Karl J; Zink K; Bittner T; Mattsson N; Eichenlaub U; Blennow K; Hansson O JAMA Neurol; 2019 Sep; 76(9):1060-1069. PubMed ID: 31233127 [TBL] [Abstract][Full Text] [Related]
29. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults. McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781 [TBL] [Abstract][Full Text] [Related]
30. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117 [TBL] [Abstract][Full Text] [Related]
31. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726 [TBL] [Abstract][Full Text] [Related]
32. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Benedet AL; Brum WS; Hansson O; ; Karikari TK; Zimmer ER; Zetterberg H; Blennow K; Ashton NJ Alzheimers Res Ther; 2022 Feb; 14(1):26. PubMed ID: 35130933 [TBL] [Abstract][Full Text] [Related]
33. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals. Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146 [TBL] [Abstract][Full Text] [Related]
34. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
39. Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers. Kwon HS; Lee EH; Kim HJ; Park SH; Park HH; Jeong JH; Koh SH; Choi SH; Lee JH Alzheimers Dement (Amst); 2023; 15(4):e12502. PubMed ID: 38026758 [TBL] [Abstract][Full Text] [Related]
40. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Rissman RA; Langford O; Raman R; Donohue MC; Abdel-Latif S; Meyer MR; Wente-Roth T; Kirmess KM; Ngolab J; Winston CN; Jimenez-Maggiora G; Rafii MS; Sachdev P; West T; Yarasheski KE; Braunstein JB; Irizarry M; Johnson KA; Aisen PS; Sperling RA; Alzheimers Dement; 2024 Feb; 20(2):1214-1224. PubMed ID: 37932961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]